JMIR Publications

ABSTRACT

Background:

Bone metastasis is a prevalent complication of malignant tumors, often resulting in restricted mobility, severe pain, and diminished quality of life.

Objective:

To assess the analgesic efficacy and safety of the Co-ablation System in patients with bone metastases.

Methods:

This retrospective study included patients with histologically confirmed bone metastases who underwent treatment with the Co-ablation System between January 2024 and October 2024. Pain was assessed using the Numerical Rating Scale (NRS) at baseline and at 1 day, 1 week, 4 weeks, 8 weeks, and 12 weeks after treatment. Functional status was evaluated using the Karnofsky Performance Status (KPS) score at baseline and at 1 week, 4 weeks, 8 weeks, and 12 weeks. Complications and changes in analgesic use were recorded. Wilcoxon signed-rank test was used for statistical analysis.

Results:

Nine patients (mean age 60.78 ± 9.04 years) were included. Primary tumors included hepatocellular carcinoma (n=4), lung adenocarcinoma (n=4), and colon adenocarcinoma (n=1). Metastatic sites involved the femur (n=3), ilium (n=4), and ribs (n=2). The mean baseline NRS score was 5.11 ± 1.05, which demonstrated a significant reduction in pain at 1 week, 4 weeks, 8 weeks, and 12 weeks (P < 0.05). KPS scores improved numerically at follow-up but did not reach statistical significance (P ＞ 0.05). No ablation-related complications occurred. At 12 weeks, four patients reduced analgesic use; none required dose escalation.

Conclusions:

The Co-ablation System is a safe and effective option for managing pain in patients with bone metastases. It provides significant pain relief and may reduce the need for analgesics. Clinical Trial: No.